408 related articles for article (PubMed ID: 31404620)
21. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.
Merker A; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1741-50. PubMed ID: 25347329
[TBL] [Abstract][Full Text] [Related]
22. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
Kaye KS; Udeani G; Cole P; Friedland HD
Hosp Pract (1995); 2015; 43(3):144-9. PubMed ID: 25956849
[TBL] [Abstract][Full Text] [Related]
23. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
24. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
25. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.
Lipsky BA; Cannon CM; Ramani A; Jandourek A; Calmaggi A; Friedland HD; Goldstein EJ
Diabetes Metab Res Rev; 2015 May; 31(4):395-401. PubMed ID: 25417910
[TBL] [Abstract][Full Text] [Related]
26. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM; Wilcox MH; Stein GE
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
28. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
29. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
Jones RN; Farrell DJ; Mendes RE; Sader HS
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii69-80. PubMed ID: 21482572
[TBL] [Abstract][Full Text] [Related]
30. A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection.
Arshad S; Hartman P; Zervos MJ
Expert Rev Anti Infect Ther; 2014 Jul; 12(7):727-9. PubMed ID: 24898885
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
Li J; Das S; Zhou D; Al-Huniti N
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
[TBL] [Abstract][Full Text] [Related]
32. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
34. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
Garrison MW; Kawamura NM; Wen MM
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
[TBL] [Abstract][Full Text] [Related]
35. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Poon H; Chang MH; Fung HB
Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
[TBL] [Abstract][Full Text] [Related]
36. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
[TBL] [Abstract][Full Text] [Related]
37. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
Parish D; Scheinfeld N
Curr Opin Investig Drugs; 2008 Feb; 9(2):201-9. PubMed ID: 18246523
[TBL] [Abstract][Full Text] [Related]
38. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010.
Flamm RK; Sader HS; Jones RN
Braz J Infect Dis; 2013; 17(5):564-72. PubMed ID: 23916453
[TBL] [Abstract][Full Text] [Related]
39. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
40. Ceftaroline fosamil: drug profile and clinical data.
Kanafani ZA
Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]